Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer.

Richman, Juliet; Ring, Alistair; Dowsett, Mitch; Sestak, Ivana

Richman, Juliet; Ring, Alistair; Dowsett, Mitch; Sestak, Ivana.

Afiliación

Richman J; Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital NHS Foundation Trust, London, UK. julietrichman@doctors.org.uk.
Ring A; Breast Unit, Royal Marsden Hospital NHS Foundation Trust, London, UK.
Dowsett M; Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital NHS Foundation Trust, London, UK.
Sestak I; Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK.

Breast Cancer Res Treat ; 186(1): 115-123, 2021 Feb.

Article en En | MEDLINE | ID: mdl-33222093

Asunto(s)

Neoplasias de la Mama; Receptores de Estrógenos; Antineoplásicos Hormonales/uso terapéutico; Neoplasias de la Mama/tratamiento farmacológico; Neoplasias de la Mama/epidemiología; Femenino; Humanos; Recurrencia Local de Neoplasia/epidemiología; Pronóstico; Estudios Retrospectivos; Tamoxifeno/uso terapéutico

Palabras clave

Breast cancer; Extended endocrine therapy; Late metastasis; Prediction

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Receptores de Estrógenos Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Año: 2021 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google